These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30753655)

  • 41. Treatment resistant depression: A multi-scale, systems biology approach.
    Akil H; Gordon J; Hen R; Javitch J; Mayberg H; McEwen B; Meaney MJ; Nestler EJ
    Neurosci Biobehav Rev; 2018 Jan; 84():272-288. PubMed ID: 28859997
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression.
    Zhdanava M; Karkare S; Pilon D; Joshi K; Rossi C; Morrison L; Sheehan J; Lefebvre P; Lopena O; Citrome L
    Adv Ther; 2021 Sep; 38(9):4900-4916. PubMed ID: 34368919
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic impact of treatment-resistant depression: A retrospective observational study.
    Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E
    J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort.
    Korchia T; Faugere M; Suc N; Garosi A; Andrieu-Haller C; Breyton M; Godin O; Aouizerate B; Arbus C; Bennabi D; Bellivier F; Bougerol T; Camus V; Courtet P; Doumy O; El-Hage W; Genty JB; Haffen E; Holtzmann J; Horn M; Leboyer M; Llorca PM; Maruani J; Moirand R; Moliere F; Petrucci J; Rey R; Samalin L; Stephan F; Vaiva G; Walter M; Yrondi A; Boyer L; Lancon C; Richieri R; Fond G;
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 114():110479. PubMed ID: 34826559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defining treatment-resistant depression: a comprehensive review of the literature.
    Trevino K; McClintock SM; McDonald Fischer N; Vora A; Husain MM
    Ann Clin Psychiatry; 2014 Aug; 26(3):222-32. PubMed ID: 25166485
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study.
    Huang SS; Chen HH; Wang J; Chen WJ; Chen HC; Kuo PH
    BMC Psychiatry; 2020 Nov; 20(1):541. PubMed ID: 33203427
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic burden of treatment-resistant depression among veterans in the United States.
    Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ
    Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuropsychological function before and after subcallosal cingulate deep brain stimulation in patients with treatment-resistant depression.
    Moreines JL; McClintock SM; Kelley ME; Holtzheimer PE; Mayberg HS
    Depress Anxiety; 2014 Aug; 31(8):690-8. PubMed ID: 24753183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples.
    Fabbri C; Kasper S; Kautzky A; Bartova L; Dold M; Zohar J; Souery D; Montgomery S; Albani D; Raimondi I; Dikeos D; Rujescu D; Uher R; Lewis CM; Mendlewicz J; Serretti A
    Br J Psychiatry; 2019 Jan; 214(1):36-41. PubMed ID: 30468137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is cognitive dysfunction involved in difficult-to-treat depression? Characterizing resistance from a cognitive perspective.
    López-Solà C; Subirà M; Serra-Blasco M; Vicent-Gil M; Navarra-Ventura G; Aguilar E; Acebillo S; Palao DJ; Cardoner N
    Eur Psychiatry; 2020 Jun; 63(1):e74. PubMed ID: 32571441
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
    Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
    J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison on the clinical features in patients with or without treatment-resistant depression: A National Survey on Symptomatology of Depression report.
    Huang Y; Sun P; Wu Z; Guo X; Wu X; Chen J; Yang L; Wu X; Fang Y
    Psychiatry Res; 2023 Jan; 319():114972. PubMed ID: 36434937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study.
    Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Riva MA; Lewis CM; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110050. PubMed ID: 32738352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression.
    Hughes ZA; Neal SJ; Smith DL; Sukoff Rizzo SJ; Pulicicchio CM; Lotarski S; Lu S; Dwyer JM; Brennan J; Olsen M; Bender CN; Kouranova E; Andree TH; Harrison JE; Whiteside GT; Springer D; O'Neil SV; Leonard SK; Schechter LE; Dunlop J; Rosenzweig-Lipson S; Ring RH
    Neuropharmacology; 2013 Mar; 66():202-14. PubMed ID: 22551786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records.
    Adekkanattu P; Olfson M; Susser LC; Patra B; Vekaria V; Coombes BJ; Lepow L; Fennessy B; Charney A; Ryu E; Miller KD; Pan L; Yangchen T; Talati A; Wickramaratne P; Weissman M; Mann J; Biernacka JM; Pathak J
    J Affect Disord; 2023 Mar; 324():102-113. PubMed ID: 36529406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current treatments used in clinical practice for major depressive disorder and treatment resistant depression in England: A retrospective database study.
    Denee T; Kerr C; Ming T; Wood R; Tritton T; Middleton-Dalby C; Massey O; Desai M
    J Psychiatr Res; 2021 Jul; 139():172-178. PubMed ID: 34077893
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study.
    Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C
    JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
    Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
    J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment-Resistant Depression: Approaches to Treatment.
    Kverno KS; Mangano E
    J Psychosoc Nurs Ment Health Serv; 2021 Sep; 59(9):7-11. PubMed ID: 34459676
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers.
    Mischel NA; Balon R
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):233-235. PubMed ID: 33905639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.